Samsung Bioepis and Yuhan Collaborate for the Commercialization of Adalloce (biosimilar- adalimumab) in Korea
Shots:
- Samsung Bioepis enter into a marketing collaboration with Yuhan Corporation for the domestic sale of Adalloce in Korea to treat RA- AS- and CD
- Additionally- Samsung Bioepis is conducting domestic sales of Etoloce (biosimilar- enbrel) and Remaloce (biosimilar- Remicade)- which have been previously released- through Yuhan Corporation
- Based on the contract- the cooperation between the two companies can be further strengthened
Ref: Samsung Bioepis | Image: Samsung Bioepis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
